Francesca Battaglin and Marta Schirripa contributed equally.
Fotios Loupakis and Sara Lonardi are Co-senior.
Few data are available regarding the treatment of metastatic colorectal cancer elderly patients with anti-EGFR agents in combination with chemotherapy. FOLFOX plus panitumumab is a standard first-line option for RAS wild-type metastatic colorectal cancer. Slight adjustments in chemo-dosage are commonly applied in clinical practice to elderly patients, but those modified schedules have never been prospectively tested. Clinical definition of elderly (≥70 years old) patients that may deserve a more or less intensive combination therapy is still debated. Several geriatric screening tools have been developed to predict survival and risk of toxicity from treatment. Among those, the G8 screening tool has been tested in cancer patients showing the strongest prognostic value for overall survival, while the CRASH score can stratify patients according to an estimated risk of treatment-related toxicities.
The PANDA study is a prospective, open-label, multicenter, randomized phase II trial of first-line therapy with panitumumab in combination with dose-adjusted FOLFOX or with 5-fluorouracil monotherapy, in previously untreated elderly patients (≥70 years) with RAS and BRAF wild-type unresectable metastatic colorectal cancer. RAS and BRAF analyses are centralized. Geriatric assessment by means of G8 and CRASH score is planned at baseline and G8 will be re-evaluated at disease progression. The primary endpoint is duration of progression-free survival in both arms. Secondary endpoints include prospective evaluation of the prognostic role of G8 score and the correlation of CRASH risk categories with toxicity.
The PANDA study aims at exploring safety and efficacy of panitumumab in combination with FOLFOX or with 5FU/LV in elderly patients affected by RAS and BRAF wild-type metastatic colorectal cancer, to identify the most promising treatment strategy in this setting. Additionally, this is the first trial in which the prognostic role of the G8 score will be prospectively evaluated. Results of this study will drive further experimental developments for one or both combinations.
NJ MC, Dotan E, Browner I. Refining the chemotherapy approach for older patients with colon cancer. J Clin Oncol. 2014;32:2570–80. CrossRef
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon cancer. Version 1.2017. Avalable at. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf [Last accessed 15 Oct 2017
Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol. 2016;34:179–85. CrossRefPubMed
EMJ VB, de Boer A, Beijnen JH, JHM S. BRAF mutations as predictive biomarker for response to anti-EGFR monoclonal antibodies. Oncologist. 2017;22(7):864–72. CrossRef
Douillard JY, Siena S, Peeters M, et al. Impact of baseline age on efficacy and safety of first-line panitumumab (pmab) + FOLFOX4 vs FOLFOX4 treatment. Ann Oncol. 2014;25(Suppl 4):iv167–209. https://doi.org/10.1093/annonc/mdu333.
Sastre J, Massuti B, Pulido G, et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish cooperative Group for the Treatment of digestive Tumours. Eur J Cancer. 2015;51:1371–80. CrossRefPubMed
Liuu E, Canoui-Poitrine F, Tournigand C. External validation of the G8 geriatric screening tool to identify vulnerable elderly cancer patients: the ELCAPA-02 study [abstract]. J Geriatr Oncol. 2012;3(Suppl 45):P23.
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 24 Aug 2017.
http://eforms.moffitt.org/crashscore.aspx. Accessed 24 Aug 2017.
García Alfonso P, Benavides M, Ruiz AS, et al. Phase II study of first-line mFOLFOX plus cetuximab (C) for 8 cycles followed by mFOLFOX plus C or single agent (s/a) C as maintenance therapy in patients (p) with metastatic colorectal cancer (mCRC): the MACRO-2 trial (Spanish cooperative Group for the Treatment of digestive tumors [TTD]). Ann Oncol. 2014;25(Suppl 4):iv167.
Arnold D, Lueza B, Douillard JY et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Ann Oncol. 2017;28(8):1713–729. https://doi.org/10.1093/annonc/mdx175.
The COBRA Study. EU Clinical Trials Register. EudraCT identifier. 2017;2017-002207-98.
- The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
Eufemia Stefania Lutrino
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II